Michelle T. Long, MD
Assistant Professor
Boston Medical Center
Dept of Medicine
Gastroenterology

MD, Tufts University School of Medicine



I am an early career physician scientist primarily interested in patient-oriented research investigating fibrosis and inflammation in patients with non-alcoholic fatty liver disease (NAFLD). My clinical and research interests center on the relationship between NAFLD and cardiovascular disease. My research is primarily based at the Framingham Heart Study where I am the PI of a study evaluating the prevalence and risk factors for liver fat (steatosis) and fibrosis. I am investigating the clinical and genetic correlates of hepatic steatosis and fibrosis as measured by transient elastography. I have expertise in epidemiology, visceral fat, liver imaging including computed tomography, ultrasound, and transient elastography. I am also a clinical gastroenterologist and endoscopist.

I am additionally interested in novel therapeutics for NAFLD and Non-alcoholic steatohepatitis (NASH) and run the clinical trials for the BMC Fatty Liver Clinic.

My other research interests include alcoholic liver disease, hepatitis C, outcomes in end-stage liver disease/cirrhosis.

2016 Boston University School of Medicine: Women's Leadership Conference Selected Participant
2016 Boston University School of Medicine: Faculty Development and Diversity Grant Recipient
2015-2019 Boston University School of Medicine: NIH Loan Repayment Program Recipient
2014 Boston University School of Medicine: 3rd Place, Evans Research Day
2009 Tufts University School of Medicine: Massachusetts Medical Society Scholars Award
2009 Tufts University School of Medicine: Phi Delta Epsilon Fraternity Award
2009 Tufts University School of Medicine: Glasgow-Rubin Citation for Academic Achievement
2009 Tufts University School of Medicine: Alpha Omega Alpha
2008 Tufts University School of Medicine: Ada Draper, MD Scholarship
2008 Tufts University School of Medicine: Magna cum laude Scientific electronic exhibit award
2006-2007 Tufts University School of Medicine: Boston Albert Schweitzer Fellowship
2006-2008 Tufts University School of Medicine: USA Funds Scholarship
2004 Middlebury College: Magna cum laude


Prevalence and risk factors for hepatic steatosis and fibrosis as measured by transient elastography
03/15/2016 - 05/31/2019 (PI)
Echosens



Identifying clinical and genetic correlates of hepatic fibrosis from fatty liver disease in the…
01/12/2018 - 11/30/2022 (PI)
NIH-NIDDK
1K23DK113252-01A1

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating …
05/16/2017 - 05/16/2020 (PI)
Intercept Pharmaceuticals, Inc.

A Double-Blind, Placebo-Controlled Trial of Obeticholic Acid in Patients with moderately severe A…
10/06/2016 - 10/05/2018 (PI)
Indiana University NIH-NIAAA
4U01AA021840-05



Yr Title Project-Sub Proj Pubs
2018 Identifying clinical and genetic correlates of hepatic fibrosis from fatty liver disease in the community 1K23DK113252-01A1
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Ma J, Hennein R, Liu C, Long MT, Hoffmann U, Jacques PF, Lichtenstein AH, Hu FB, Levy D. Improved Diet Quality Associates With Reduction in Liver Fat-Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease. Gastroenterology. 2018 Mar 28. PMID: 29604292.
     
  2. Lee JJ, Pedley A, Hoffmann U, Massaro JM, Levy D, Long MT. Visceral and Intrahepatic Fat Are Associated with Cardiometabolic Risk Factors Above Other Ectopic Fat Depots: The Framingham Heart Study. Am J Med. 2018 Mar 05.View Related Profiles. PMID: 29518370.
     
  3. Long MT, Benjamin EJ. Prevalent Cardiovascular Disease Events and T1 Mapping Defined Hepatic Fibrosis. Circ Cardiovasc Imaging. 2018 Mar; 11(3):e007553.View Related Profiles. PMID: 29523556.
     
  4. Datta S, Sherva RM, De La Cruz M, Long MT, Roy P, Backman V, Chowdhury S, Roy HK. Single Nucleotide Polymorphism Facilitated Down-Regulation of the Cohesin Stromal Antigen-1: Implications for Colorectal Cancer Racial Disparities. Neoplasia. 2018 Mar; 20(3):289-294.View Related Profiles. PMID: 29471289; DOI: 10.1016/j.neo.2018.01.003;.
     
  5. Long MT, Pedley A, Massaro JM, Hoffmann U, Ma J, Loomba R, Chung RT, Benjamin EJ. A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study. Liver Int. 2018 Jan 29.View Related Profiles. PMID: 29377504.
     
  6. Shah RV, Yeri AS, Murthy VL, Massaro JM, D''Agostino R, Freedman JE, Long MT, Fox CS, Das S, Benjamin EJ, Vasan RS, O''Donnell CJ, Hoffmann U. Association of Multiorgan Computed Tomographic Phenomap With Adverse Cardiovascular Health Outcomes: The Framingham Heart Study. JAMA Cardiol. 2017 Nov 01; 2(11):1236-1246.View Related Profiles. PMID: 28975197.
     
  7. O''Sullivan JF, Morningstar JE, Yang Q, Zheng B, Gao Y, Jeanfavre S, Scott J, Fernandez C, Zheng H, O''Connor S, Cohen P, Vasan RS, Long MT, Wilson JG, Melander O, Wang TJ, Fox C, Peterson RT, Clish CB, Corey KE, Gerszten RE. Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes. J Clin Invest. 2017 Dec 01; 127(12):4394-4402.View Related Profiles. PMID: 29083323.
     
  8. Lee JJ, Pedley A, Hoffmann U, Massaro JM, O''Donnell CJ, Benjamin EJ, Long MT. Longitudinal Associations of Pericardial and Intrathoracic Fat With Progression of Coronary Artery Calcium (from the Framingham Heart Study). Am J Cardiol. 2018 Jan 15; 121(2):162-167.View Related Profiles. PMID: 29146023.
     
  9. Li W, Dorans KS, Wilker EH, Rice MB, Long MT, Schwartz J, Coull BA, Koutrakis P, Gold DR, Fox CS, Mittleman MA. Residential Proximity to Major Roadways, Fine Particulate Matter, and Hepatic Steatosis: The Framingham Heart Study. Am J Epidemiol. 2017 Oct 01; 186(7):857-865. PMID: 28605427.
     
  10. Kimberly WT, O''Sullivan JF, Nath AK, Keyes M, Shi X, Larson MG, Yang Q, Long MT, Vasan R, Peterson RT, Wang TJ, Corey KE, Gerszten RE. Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis. JCI Insight. 2017 May 04; 2(9).View Related Profiles. PMID: 28469090; DOI: 10.1172/jci.insight.92989;.
     
Showing 10 of 25 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 25 publications over 5 distinct years, with a maximum of 8 publications in 2017

YearPublications
20071
20155
20166
20178
20185
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

cardiovascular disease
Epidemiology
Fibrosis
Hepatology
Inflammation
Non-alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic Steatohepatitis (NASH)
Risk Stratification

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
  • Work / Life Integration Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')


818 Harrison Ave
Boston MA 02118
Google Map

617.638.8392
Download vCard

Long's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (102) concept(s)
_
Co-Authors
See all (23) people
_
Similar People
See all (60) people
_
Same Department
Search Department